PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 73 news outlets
blogs: 4 blogs
policy: 1 policy source
twitter: 311 X users
patent: 31 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 952 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details - Cemiplimab (Libtayo) CSCC – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 09 Jul 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.